Breathing Freely is
a Fundamental Right
Bayu Healthcare's complete COPD inhaler portfolio — built on the latest GOLD 2026 guidelines, driven by the mission of making world-class respiratory care accessible to every patient.
Understanding COPD
Chronic Obstructive Pulmonary Disease — a progressive, preventable, and treatable disease that silently robs millions of Indians of the ability to breathe freely.
What is COPD?
COPD is a chronic inflammatory lung disease characterised by persistent respiratory symptoms and progressive airflow limitation, usually caused by long-term exposure to harmful gases or particles — most commonly tobacco smoke, biomass fuel, and occupational dust.
GOLD 2026 — New Definition
GOLD 2026 reframes COPD as a disease of ongoing activity — characterised by active inflammation, symptom variability, and ongoing exacerbation risk — not merely static airflow limitation. The therapeutic goal is achieving and maintaining a "low disease activity state."
Common Symptoms
Progressive breathlessness, chronic productive cough, wheeze, increased sputum, reduced exercise tolerance, and fatigue.
India-Specific Risk Factors
Biomass fuel combustion (cooking over wood/dung), tobacco/bidi smoking, occupational dust exposure, post-tuberculosis obstructive lung disease, and low birth weight.
Diagnosis
Confirmed by spirometry: post-bronchodilator FEV₁/FVC ratio < 0.70. Severity graded by FEV₁ % predicted (GOLD Grades 1–4). Spirometry is grossly underused in India — most COPD remains undiagnosed.
Disease Progression
Without treatment, COPD worsens over time. Each acute exacerbation accelerates lung function decline, raises hospitalisation risk, and increases mortality. Early, sustained treatment is the only way to preserve quality of life.
GOLD 2026: ABE Classification — Who Needs What Treatment?
GOLD 2026 classifies COPD patients into three groups based on symptom burden and exacerbation history, guiding precise pharmacotherapy choices.
| Group | Symptom Burden | Exacerbation History | Recommended First Therapy |
|---|---|---|---|
| Group A | Low (mMRC 0–1 / CAT < 10) | 0 exacerbations | Single bronchodilator (LAMA preferred) |
| Group B | High (mMRC ≥ 2 / CAT ≥ 10) | 0 exacerbations | LABA + LAMA (dual bronchodilation) |
| Group E | Any level | ≥ 1 moderate exacerbation or hospitalisation | LABA + LAMA; add ICS (triple) if BEC ≥ 300 cells/μL |
BEC = Blood Eosinophil Count | mMRC = Modified Medical Research Council Dyspnoea Scale | CAT = COPD Assessment Test
Uphale™
Uphale — Tiotropium 18 mcg DPI
Once-daily Long-Acting Muscarinic Antagonist (LAMA) — the gold standard first-line bronchodilator for COPD maintenance therapy. Every breath, every day.
About the Molecule — Tiotropium
Tiotropium Bromide
Tiotropium is the most extensively studied and prescribed LAMA in the world. It provides sustained, 24-hour bronchodilation through selective, kinetically slow blockade of M₁ and M₃ muscarinic receptors in airway smooth muscle and glands.
- Blocks M₁/M₃ muscarinic receptors — preventing acetylcholine-driven bronchoconstriction
- Reduces dynamic hyperinflation — the key driver of breathlessness on exertion in COPD
- Improves inspiratory capacity by up to 300 mL — directly enabling better exercise tolerance
- Reduces mucus hypersecretion from airway glands
- Once-daily dosing — due to kinetically slow dissociation from M₃ receptors (half-life ~35 hours)
- Minimal systemic absorption from the inhaled route — excellent safety profile
🔬 Key Clinical Evidence
Who Should Receive Uphale?
💊 Correct Inhalation Technique
- Remove capsule from blister; place in chamber of DPI device
- Press the piercing buttons firmly — once
- Exhale fully — away from the device
- Seal lips around mouthpiece; inhale deeply and forcefully
- Hold breath for 5–10 seconds
- Repeat inhalation from same capsule to ensure complete dose
Uphale Plus™
Uphale Plus — Dual Bronchodilation in One Capsule
Two complementary bronchodilators. Two distinct mechanisms. One powerful capsule DPI — delivering superior symptom control and lung function improvement versus either agent alone.
Tiotropium Bromide (18 mcg)
Once-daily muscarinic antagonist providing sustained 24-hour bronchodilation through selective M₁ and M₃ receptor blockade. Reduces hyperinflation and improves inspiratory capacity — addressing the mechanical limitation of COPD at its root.
- Selective M₁/M₃ antagonism — blocks acetylcholine-driven airway narrowing
- Reduces dynamic hyperinflation — the dominant cause of exertional dyspnoea
- Slows mucus secretion — less sputum burden on airways
- 24-hour duration — single dose provides all-day and all-night protection
Formoterol Fumarate (12 mcg)
A rapid-onset, 12-hour LABA unique in combining fast bronchodilation (onset 3–5 minutes) with sustained maintenance action. Provides complementary bronchodilation via a completely different receptor pathway to tiotropium.
- β₂ adrenergic receptor agonism — direct relaxation of airway smooth muscle
- Rapid onset (3–5 min) — fastest-acting LABA; acts as maintenance AND reliever
- 12-hour sustained action — twice-daily dosing covers day and night
- Additive bronchodilation with LAMA — superior FEV₁ improvement vs. either alone
- Anti-inflammatory synergy with ICS when used in combination
The LAMA + LABA Advantage
Combining both classes provides complementary bronchodilation that exceeds what either agent achieves alone — through two independent receptor systems working simultaneously.
- LAMA reduces airway smooth muscle tone via muscarinic blockade
- LABA relaxes airway smooth muscle via β₂ stimulation
- Combined FEV₁ improvement superior to monotherapy by ~80–100 mL
- Superior reduction in exacerbations vs. LAMA or LABA alone in Group B/E
- GOLD 2026: Dual bronchodilation is first-line for Group B patients
🔬 Clinical Evidence — Dual Bronchodilation
Who Should Receive Uphale Plus?
Fabhale-G™
Fabhale-G — The Complete COPD Shield
Triple therapy in a single capsule DPI. Three molecules. Three mechanisms. The most comprehensive pharmacological protection available for severe COPD — now made accessible for Indian patients.
Glycopyrronium (LAMA)
A once-daily Long-Acting Muscarinic Antagonist providing potent, sustained 24-hour bronchodilation. Glycopyrronium is structurally optimised for rapid airway receptor binding with prolonged retention — offering fast onset alongside all-day protection.
- Selective M₃ muscarinic receptor antagonism in bronchial smooth muscle
- Rapid onset of action — faster than tiotropium in some studies
- 24-hour duration — comprehensive round-the-clock bronchodilation
- Reduces static and dynamic hyperinflation
- Improves inspiratory capacity and reduces resting dyspnoea
Formoterol Fumarate (LABA)
The rapid-onset, 12-hour LABA — providing complementary bronchodilation via β₂ adrenergic receptor pathway alongside Glycopyrronium's muscarinic blockade. Together, they provide complete and superior dual bronchodilation as the functional core of triple therapy.
- β₂ adrenergic agonism — direct smooth muscle relaxation
- Onset in 3–5 minutes — fastest clinically meaningful LABA onset
- Anti-inflammatory synergy with Budesonide (ICS) in triple combination
- Additive bronchodilation with Glycopyrronium — FEV₁ maximised
- 12-hour coverage — twice-daily dosing for day and night protection
Budesonide (ICS)
One of the most extensively studied inhaled corticosteroids in global respiratory medicine. Budesonide provides potent, local anti-inflammatory activity in the airways — addressing the eosinophilic inflammation that LAMA and LABA alone cannot reverse.
- Topical glucocorticoid — suppresses eosinophilic airway inflammation
- Reduces airway oedema, mucus secretion, and hyperresponsiveness
- High first-pass hepatic metabolism — minimal systemic corticosteroid side effects
- Dramatically reduces exacerbation frequency in eosinophilic COPD
- Synergistic with Formoterol — dual combination within the triple regimen
Why Triple Therapy Changes Everything
In GOLD Group E patients with blood eosinophil count ≥ 300 cells/μL, bronchodilation alone is insufficient. Active eosinophilic inflammation drives recurrent exacerbations that LAMA+LABA cannot address. Adding inhaled corticosteroid (Budesonide) directly suppresses this inflammatory driver.
🔬 Landmark Clinical Trials — Triple Therapy
Who Should Receive Fabhale-G?
The Bayu COPD Therapeutic Ladder
Every step of the GOLD 2026 treatment pathway covered. From first diagnosis to most severe disease — Bayu Healthcare has a brand for every patient.
Which Brand for Which Patient?
A quick clinical decision guide — matching the right Bayu brand to the right patient at every step of their COPD journey.
Common Patient Scenarios → Recommended Bayu Brand
Newly diagnosed COPD, mild breathlessness (mMRC 1), no exacerbations, GOLD Grade 1–2
Patient needs simple, once-daily maintenance. LAMA monotherapy is the GOLD 2026 first choice.
→ Uphale (Tiotropium 18 mcg) — Once DailyCOPD on Uphale alone with persistent breathlessness (CAT ≥ 10 / mMRC ≥ 2), no hospitalisations
GOLD Group B — step up to dual bronchodilation. BEC not needed for this step-up decision.
→ Uphale Plus (Tiotropium + Formoterol) — Twice DailyCOPD patient with ≥ 1 exacerbation in last year, BEC 120 cells/μL — moderate disease
GOLD Group E, low eosinophils — ICS not strongly indicated. Dual bronchodilation is correct therapy.
→ Uphale Plus (LAMA+LABA) — avoid ICS (BEC < 300)COPD patient discharged after hospitalisation, BEC 380 cells/μL, GOLD Grade 3
GOLD Group E + high eosinophils — this is the precise indication for triple therapy. Do not wait.
→ Fabhale-G (Triple: Glycopyrronium + Formoterol + Budesonide)Patient currently on competitor LABA+ICS (e.g. at ₹391/pack) — seeking more affordable option
Same clinical combination. Dramatically lower price. Sustained adherence becomes possible.
→ Switch to Fabhale 400 (Formoterol + Budesonide 400 mcg) — ₹150
#RTI — Right to Inhalation
Because Every Breath Matters
Across India, millions of patients with COPD and asthma are prescribed dry powder inhalers — the gold standard of care. Yet a profound number of these patients stop using their inhalers the moment their symptoms ease. The reason is not ignorance. It is price.
A single high-strength combination inhaler can cost upwards of ₹391 per pack on the open market. For a daily agricultural worker or a lower-income family, that price forces an impossible choice: medicine or food. The cycle that follows — symptom return, emergency care, brief relief, medication abandonment — is heartbreaking and entirely preventable.
This is the crisis #RTI — Right to Inhalation was born to address. It is not merely a pricing initiative. It is a declaration that affordable respiratory care is a human right — and Bayu Healthcare has built its entire COPD portfolio around this belief.
The #RTI Price Difference
These are not subsidised prices. They reflect Bayu Healthcare's commitment to manufacturing efficiency, fair margins, and a mission-driven pricing philosophy that puts patients before profit.
Affordable Medicine
World-class DPI formulations priced within the reach of lower-income patients — because the best prescription is one the patient can actually fill, every month, for life.
Doctor Partnership
Prescribing with access in mind is a clinical act of equity. We invite every doctor to become an active #RTI partner — choosing Bayu brands for price-sensitive patients without compromising on clinical quality.
Last-Mile Reach
Through ASHA workers, rural health camps, community pharmacies, and telemedicine, the #RTI message reaches patients in every district — not just in cities.
Patient Education
Regional-language leaflets, DPI technique clinics, and adherence counselling — because affordability alone isn't enough. Patients must understand why daily inhalation therapy changes their lives.
"Thousands of patients like Jai — daily agricultural workers who once chose food over medicine — are now on continuous maintenance therapy with Fabhale. For three years, he has not missed a dose because of cost. He has not been hospitalised. He works. He is present for his family. He breathes freely."
— #RTI Patient Story | Bayu Healthcare
Join the movement: